Indoleamine 2,3-dioxygenase (IDO) Inhibitors and Cancer Immunotherapy

The development and approval of immune checkpoint (programmed cell death protein 1 [PD-1], programmed death-ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4], and lymphocyte-activation gene 3 [LAG-3]) inhibitors resulted in dramatic changes in the landscape of cancer therapy. Still, most patients treated with an immune checkpoint inhibitor, especially with a monotherapy approach, will demonstrate either primary or acquired resistance to these treatments, which has led to clinical research focusing on therapeutic options utilizing combination strategies with immune checkpoint inhibitors and other agents [1 –4].

Source: Cancer Treatment Reviews - August 30, 2022 Category: Cancer & Oncology Authors: Yu Fujiwara, Shumei Kato, Mary K Nesline, Jeffrey M Conroy, Paul DePietro, Sarabjot Pabla, Razelle Kurzrock Source Type: research